Three U.S. Patents Awarded to Capitainer for Plasma/Serum Separation Device

Capitainer has been granted three U.S. patents for its soon-to-be launched plasma/serum separation device. The patents cover the company’s technology for automatic separation and metering from whole blood.

“These patents reinforce our strategic position, facilitating Capitainer’s expansion in the U.S. market,” Capitainer CEO Christopher Aulin said. “The recognition from the United States Patent Office is a testament to the technological advancements we’ve achieved. This enables us to extend our advanced solutions to a broader range of healthcare providers and researchers.” 
 
The U.S. Patent and Trademark Office granted Capitainer three patents related to its plasma/serum separation device, Capitainer SEP10. The patents cover the developed microfluidic solutions that enable patients to sample their blood at home without any more demands than applying a fresh sample (from a finger) to the card. The patents ensure that Capitainer’s technology is patent-protected in the United States until at least 2042. Additionally, there are several patent applications currently pending in various markets worldwide.
 
“Our solution is unique on the market, having solved the technical challenges that enable whole blood separation of cells from plasma/serum. While the patient engages in the initial step of pricking their finger and applying the blood to the card, our technology then takes over. It automates the subsequent processes of separation and precise volume measurement,” Capitainer R&D Manager Anna Ohlander stated. “This solution aligns with the overall characteristics of the Capitainer sampling platform to make it easy to sample accurately with quality for clinical diagnostics.”
 
With the North America blood testing market size estimated to reach $43.4 billion by 2032, the United States constitutes one of the largest potential commercial opportunities for Capitainer. The company’s technology is protected by a broad patent portfolio in major geographic markets and the firm boasts six patent families. 
 
Capitainer AB is a Swedish medtech company founded in 2016 that develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed unique technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies.